Spotlight on Hematology
Management of Waldenström’s Macroglobulinemia in the Era of Targeted Therapies
StartActivity Details
1.0 Contact Hour(s)
Expires: May 12, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
- Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
- Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA
Dr. Treon has provided the following disclosure information:
- Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
- Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: May 12, 2023
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of community oncologists, hematologists, hematologists/oncologists, oncology nurses, NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with Waldenström’s Macroglobulinemia.
Learning Objectives
After completing this program, participants should be able to:
- Discuss the criteria for diagnosis and initiation of therapy for patients with Waldenström’s Macroglobulinemia, and use this information to guide initial workup and treatment decision-making
- Assess the safety and efficacy of practice-changing clinical trial findings of current and emerging agents for Waldenström’s Macroglobulinemia
- Integrate current guidelines, available clinical trial data, and real-world findings into individualized strategies for treatment selection, sequencing, and monitoring of Waldenström’s Macroglobulinemia
Activity Description
This education activity is designed to provide the healthcare team with the latest developments and critical insights into treating their patients with Waldenström’s Macroglobulinemia. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
The treatment of Waldenström’s Macroglobulinemia (WM) patients should be highly personalized, and the patient’s clinical presentation, comorbidities, genomic profile, and preferences, as well as toxicity of the treatment regimens, should be taken into account. Considering the continued evolution of therapeutic modalities and management strategies for WM and the information burden placed on busy community healthcare professionals who may have little to no experience with WM, expert guidance and interpretation of the clinical significance of emerging clinical data would benefit those caring for patients with WM, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Professor of Medicine, Harvard Medical School
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana Farber Cancer Center
Boston, MA
Dr. Treon has provided the following disclosure information:
- Research Support/P.I.: AbbVie/Pharmacyclics, Beigene, BMS, Eli Lilly
- Consultant: Janssen, AbbVie/Pharmacyclics, Beigene, BMS
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks for participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by an educational grant from Ascentage Pharma Group, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Hematology Presentations
No programs are available for this specialty. Check back later.